Eli Lilly Co. has monoclonal antibodies in human trials and said the treatment for COVID-19 could gain emergency-use government approval as early as September.
It is designed to reduce the severity of the virus, keeping patients out of hospitals.
Daniel Skovronsky, Lilly’s chief scientific officer, said the therapies – which may also be used to prevent the disease – could beat a vaccine to widespread use as a COVID-19 treatment, if they prove effective.
